Lundbeck to make bond debut after drug news

Headache_Adobe_230x150
By Mike Turner
25 Feb 2020

H Lundbeck, the Danish pharmaceutical company, has mandated banks for a five year debut euro benchmark from its new bond programme, after gaining US regulatory approval for a new migraine treatment.

The company, rated BBB- by S&P for the first time on Tuesday, has hired Bank of America, BNP Paribas, Danske Bank and Nordea as bookrunners to arrange investor meetings starting on Friday.

The deal is mainly to refinance Lundbeck's October 2019 acquisition of US-focused Alder Biopharmaceuticals for around $1.95bn.

Lundbeck ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial